Goodnites Skin Tag Remover

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts.

Limitations of Use This drug is not intended for use on facial warts, genital warts, or warts on mucous membranes. It should be used only as directed for the specified conditions.

Dosage and Administration

Adults and children aged 2 years and older should begin treatment by washing the affected area. Soaking the wart in warm water for 5 minutes is optional but may enhance the effectiveness of the treatment. After washing, the area must be dried thoroughly.

The medication should be applied using an applicator or brush, with one drop or a small amount applied at a time to ensure sufficient coverage of each wart. It is important to allow the application to dry completely before proceeding.

Treatment may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

For children under 2 years of age, it is advised to consult a physician before use.

Contraindications

Use is contraindicated in the following situations:

Application is not recommended on irritated, infected, or reddened skin due to the potential for exacerbating these conditions. The product should not be applied to moles, birthmarks, warts with hair, genital warts, warts on the face, or mucous membranes, as these areas may be sensitive or require specialized treatment. Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of adverse effects.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product is contraindicated for application on irritated, infected, or reddened skin. It should not be used on moles, birthmarks, warts with hair, genital warts, warts on the face, or on mucous membranes. Additionally, individuals with diabetes or poor blood circulation should refrain from using this product.

Users are advised to discontinue use if the condition worsens, if excessive irritation develops, or if unexpected side effects occur. Care should be taken to avoid contact with the eyes and mucous membranes. While mild irritation may be a common occurrence, should excessive irritation arise, it is imperative to stop use and consult a healthcare professional.

Side Effects

Patients should be aware that the product is intended for external use only. In clinical practice, there are several adverse reactions that may necessitate discontinuation of use. Patients are advised to stop using the product if the condition worsens, if excessive irritation develops, or if they experience unexpected side effects.

These reactions highlight the importance of monitoring for any changes in skin condition or unexpected responses during treatment. It is essential for patients to communicate with their healthcare provider regarding any adverse reactions experienced while using the product.

Drug Interactions

No specific drug interactions have been identified for this medication. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Goodnites Skin Tag Remover (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 2 years of age should consult a healthcare professional before use. For children aged 2 years and older, the affected area should be washed, and optionally, warts may be soaked in warm water for 5 minutes. The area must be dried thoroughly before applying one drop or a small amount of the product with an applicator or brush to adequately cover each wart. After application, the area should be allowed to dry. Treatment may be repeated once or twice daily as needed until the wart is removed, with a maximum duration of up to 12 weeks.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The safety of this medication during pregnancy has not been specifically established. There are no available data regarding the potential risks or fetal impacts associated with its use in pregnant patients. Healthcare professionals should exercise caution when prescribing this medication to women of childbearing potential and consider the lack of information regarding its effects on pregnancy and fetal outcomes. It is advisable to weigh the potential benefits against any unknown risks when making treatment decisions for pregnant patients.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or any lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. It is advisable to consult local poison control centers or relevant medical authorities for guidance on management protocols specific to the medication in question.

Documentation of the incident, including the amount ingested and the time of exposure, is crucial for effective management and treatment planning. Continuous monitoring of the patient's vital signs and clinical status is also recommended until the patient is stabilized.

Nonclinical Toxicology

No information is available regarding teratogenic or non-teratogenic effects. Additionally, there is no data provided concerning nonclinical toxicology, animal pharmacology, or toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is important to emphasize the necessity of avoiding contact with the eyes and mucous membranes to prevent potential harm.

Patients should be informed that mild irritation may occur during use. However, if they experience excessive irritation, they should discontinue use and consult a healthcare professional for further guidance.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

Patients aged 2 years and older should wash the affected area, optionally soaking the wart in warm water for 5 minutes, and then dry the area thoroughly. A small amount of the product should be applied with an applicator or brush to sufficiently cover each wart, allowing it to dry. This process may be repeated once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. For children under 2 years, consultation with a doctor is advised.

Clinicians should counsel patients to avoid contact with eyes and mucous membranes, as some mild irritation may occur. If excessive irritation develops, patients are advised to discontinue use and consult a doctor.

Drug Information (PDF)

This file contains official product information for Goodnites Skin Tag Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)